US Patent 11136381 Anti-C3 antibodies
Patent 11136381 was granted and assigned to NGM Biopharmaceuticals on October, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+370 characters)
Article
Patent abstract
The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
Edits on 27 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111363810
Date of Patent
October 5, 2021
0Patent Application Number
201904010
Date Filed
April 1, 2019
0Official Website
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111363810
Date of Patent
October 5, 2021
0Patent Application Number
201904010
Date Filed
April 1, 2019
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11136381 Anti-C3 antibodies
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11136381
Date of patent
October 5, 2021
Patent application number
20190401
Date Filed
April 1, 2019
Find more entities like US Patent 11136381 Anti-C3 antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.